10.1371/journal.pone.0176970.g007 Alok Raghav Alok Raghav Jamal Ahmad Jamal Ahmad Khursheed Alam Khursheed Alam Nonenzymatic glycosylation of human serum albumin and its effect on antibodies profile in patients with diabetes mellitus - Fig 7 Public Library of Science 2017 CKD Nonenzymatic glycosylation 1737 cm -1. LCMS chromatogram HSA manifests mg carbonyl group glucose CML diabetes mellitus type 2 diabetes mellitus type 2 glycated-HSA UV GDM antibody Amide II peak neo-epitopes generation complication peak appearance carboxymethyl lysine Modified samples λ 280 nm 2DM anincreasein fluorescence intensity binding enzyme-linked immunosorbent assay kidney disease auto-antibodies formation FTIR results Conclusions Non-enzymatic glycosylation anantigen concentration diabetes mellitus Background Albumin glycation Results Glycated-HSA Neo-epitopesagainst In-vitro Liquid chromatography mass spectrometry antibodies profile binding ELISA amarked increase 1DM glycation end products 40 day period Methods Human Serum Albumin serum albumin 2017-05-17 17:37:12 Figure https://plos.figshare.com/articles/figure/Nonenzymatic_glycosylation_of_human_serum_albumin_and_its_effect_on_antibodies_profile_in_patients_with_diabetes_mellitus_-_Fig_7/5014130 <p>(a) Inhibition of binding of affinity purified anti-HSA IgG and pre-imune IgG to native HSA. Microtitre plates were coated with native HSA (10 μg/mL). (b) Inhibition of binding of affinity purified anti-glucose-HSA IgG and pre-imune IgG to glucose modified HSA. Microtitre plates were coated with native HSA (10 μg/mL).</p>